文献速递外周动脉疾病

外周介入中「失败无法通过」:未获报销的操作

"Failure-to-Cross" in Patients Undergoing Percutaneous Peripheral Intervention: The Nonreimbursed Procedure.
PubMed 文献 · Ann Vasc Surg · 2020-06-27

该研究回顾性分析了单中心2年内146例外周介入手术,发现「失败无法通过」发生率为11.6%(17例)。失败病例的透视时间、室内时间和造影剂用量与成功病例无显著差异,但医院收费与成本远高于单纯诊断性造影,而操作者获得的报销却与诊断性操作相同。结论认为,病变无法通过的患者预后更差,且操作者在失败操作中得不到合理补偿。

要点

  • 外周介入中「失败无法通过」发生率约11.6%,多数为男性且单支血管流出道。
  • 失败操作耗时与成功操作相当,但医院收费和成本显著更高。
  • 操作者报销仅按诊断性操作水平,失败操作缺乏合理补偿。

核心结论

  • 外周介入中病变无法通过的患者预后较成功干预者更差。
  • 失败操作消耗大量资源但操作者仅获得与诊断性造影相当的报销。

研究设计与样本

  • 单中心回顾性研究,连续纳入2年内146例外周介入手术。
  • 比较成功干预、失败无法通过和未尝试干预的诊断性造影三组。

主要发现

  • 失败无法通过率为11.6%(17例),其中男性占82%,单支血管流出道占53%。
  • 失败组与成功组在慢性肢体威胁性缺血(82% vs. 70%,P=0.34)和膝下闭塞性疾病(47% vs. 31%,P=0.20)发生率上无显著差异。
  • 失败组与成功组在透视时间(27±10 vs. 24±14 min,P=0.52)、室内时间(106±98 vs. 103±44 min,P=0.84)和造影剂用量(73±37 vs. 96±54 mL,P=0.12)上无显著差异。
  • 失败组医院收费和成本显著高于诊断性造影组(收费$13,311±6,067 vs. $7,690±1,942,P<0.01;成本$5,289±2,099 vs. $2,826±1,198,P<0.01)。
  • 失败组操作者平均收费$7,360,平均报销$992,与纯诊断性操作相同。

临床怎么用

  • 对于复杂闭塞病变,应充分评估通过失败的风险及资源消耗。
  • 需关注失败无法通过病例的后续治疗选择,如高级介入、外科旁路或截肢。

局限性

  • 单中心回顾性研究,样本量有限(146例)。
  • 未报告失败无法通过的具体预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Percutaneous peripheral intervention (PPI) is often the first mode of therapy for patients with symptomatic arterial occlusive disease. Technical success generally remains high although "failure-to-cross" still complicates 5-20% of cases. Extended efforts to cross long, occlusive lesions can utilize significant hospital and practitioner resources. The hospital is typically reimbursed for this effort as facility fees are charged by the hour and materials are charged per use. However, given the lack of a CPT® code for "failure-to-cross," practitioners are rarely appropriately compensated. The purpose of this study is to analyze the predictors, technical details, outcomes, and costs of "failure-to-cross" during PPI. METHODS: All PPI procedures over a 2-year period at a single institution were retrospectively reviewed. Clinical characteristics, results, costs, and reimbursements obtained from hospital cost accounting were compared among successful therapeutic interventions, crossing failures, and diagnostic angiograms without attempted intervention. RESULTS: A total of 146 consecutive PPIs were identified; the rate of "failure-to-cross" was 11.6% (17 patients). The majority of patients with "failure-to-cross" were male (82%) with single-vessel runoff (53%). Compared to successful interventions, the incidences of chronic limb-threatening ischemia (82% vs. 70%, P = 0.34) and infrapopliteal occlusive disease were similar (47% vs. 31%, P = 0.20). "Failure-to-cross" procedures were just as long as successful procedures; there were no significant differences in fluoroscopy time (27 ± 10 vs. 24 ± 14 min, P = 0.52), in-room time (106 ± 98 vs. 103 ± 44 min, P = 0.84), or contrast dye volume utilization (73 ± 37 vs. 96 ± 54 mL, P = 0.12). As expected, "failure-to-cross" procedures incurred far higher hospital charges and costs compared to noninterventional diagnostic angiograms (charges $13,311 ± 6,067 vs. $7,690 ± 1,942, P < 0.01; costs $5,289 ± 2,099 vs. $2,826 ± 1,198, P < 0.01). Despite the additional time and effort spent attempting to cross difficult lesions, the operators were reimbursed at the same low rate as a purely diagnostic procedure (average fee charge $7,360; average reimbursement $992). After 1 year, the 17 patients in whom lesions could not be crossed were treated with advanced interventional procedures with success (n = 2), surgical bypass grafting (n = 5), extremity amputation (n = 4), or no additional intervention in their salvaged limb (n = 6). CONCLUSIONS: Patients whose lesions cannot be crossed during PPI fare worse than patients undergoing successful interventions. Hospital costs and charges appropriately reflect the high technical difficulty and resource utilization of extended attempts at endovascular therapy. For practitioners, crossing lesions during PPI is truly a "pay-for-performance" procedure in that only successful procedures are reasonably reimbursed.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. El Khoury R, Cataneo JL, Paredes JA, et al. "Failure-to-Cross" in Patients Undergoing Percutaneous Peripheral Intervention: The Nonreimbursed Procedure. Ann Vasc Surg. 2020. PMID: 32603846. doi:10.1016/j.avsg.2020.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。